Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 3004089 | PO / MO |
The patient took all the four pills of Vivotif capsules together today; The patient took all the four pills of Vivotif capsules together today; Case reference number US-BN-2025-000248 is a spontaneous case initially received from nurse via Communications (reference number: USBAV25-0342) on 14-Feb-2025 and concerns a 53-years-old female patient. The patient's medical history and concomitant medication details were not provided. On 14-Feb-2025, reported as today, the patient took the all the four pills of Vivotif capsules together (*batch number: 3004089; expiration date: 30-Jun-2025*), at a dose of four capsule, orally, for typhoid immunization (explicitly coded as 'vaccine overdose' and 'inappropriate schedule of vaccine administered'). *As reported, the patient referred to primary care provider for guidance on how to proceed with dose administration*. At the time of the *follow-up* report, the patient *did not* experience any adverse event due to Vivotif. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a nurse on 27-Feb-2025: New information included patient initials, Vivotif dosing details, and confirmation that no side effects have been reported by the patient.; Reporter's Comments: A 53-years-old female patient took the all the four pills of Vivotif capsules together, at a dose of four capsule, orally, for typhoid immunization which is considered as vaccine overdose and inappropriate schedule of vaccine administered. Inappropriate schedule of product administration and overdose are both considered listed per company conventions. The patient referred to primary care provider for guidance on how to proceed with dose administration. At this point, the patient did not experience any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration and overdose are both assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 53-years-old female patient took the all the four pills of Vivotif capsules together, at a dose of four capsule, orally, for typhoid immunization which is considered as vaccine overdose and inappropriate schedule of vaccine administered. Inappropriate schedule of product administration and overdose are both considered listed per company conventions. At this point, the patient did not experience any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration and overdose are both assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None